Literature DB >> 11318818

Treatment of tularemia with levofloxacin.

E A Aranda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11318818     DOI： 10.1046/j.1469-0691.2001.00234.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


× No keyword cloud information.
  7 in total

1.  Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus).

Authors:  Michelle Nelson; Mark S Lever; Rachel E Dean; Peter C Pearce; Daniel J Stevens; Andrew J H Simpson
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

2.  Toll-like receptor 3 agonist protection against experimental Francisella tularensis respiratory tract infection.

Authors:  Richard B Pyles; G Eric Jezek; Tonyia D Eaves-Pyles
Journal:  Infect Immun       Date:  2010-02-01       Impact factor: 3.441

3.  Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody.

Authors:  Gary R Klimpel; Tonyia Eaves-Pyles; Scott T Moen; Joanna Taormina; Johnny W Peterson; Ashok K Chopra; David W Niesel; Paige Carness; Judith L Haithcoat; Michelle Kirtley; Abdelhakim Ben Nasr
Journal:  Vaccine       Date:  2008-10-16       Impact factor: 3.641

4.  Consequences of delayed ciprofloxacin and doxycycline treatment regimens against Francisella tularensis airway infection.

Authors:  Shahar Rotem; Erez Bar-Haim; Hila Cohen; Uri Elia; Raphael Ber; Avigdor Shafferman; Ofer Cohen
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

5.  Generation of a convalescent model of virulent Francisella tularensis infection for assessment of host requirements for survival of tularemia.

Authors:  Deborah D Crane; Dana P Scott; Catharine M Bosio
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

Review 6.  New therapeutic approaches for treatment of tularaemia: a review.

Authors:  Sandrine Boisset; Yvan Caspar; Vivien Sutera; Max Maurin
Journal:  Front Cell Infect Microbiol       Date:  2014-03-28       Impact factor: 5.293

7.  Nanoaerosols reduce required effective dose of liposomal levofloxacin against pulmonary murine Francisella tularensis subsp. novicida infection.

Authors:  Crystal N Propst; Albert O Nwabueze; Igor L Kanev; Rachel E Pepin; Bradford W Gutting; Victor N Morozov; Monique L van Hoek
Journal:  J Nanobiotechnology       Date:  2016-04-18       Impact factor: 10.435
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.